Table 6.
Adverse reaction by system.
| Adverse reactions | Prostanoid-naïve n = 6 (21.4%) | Transition n = 22 (78.6%) | Overall n = 28 |
|---|---|---|---|
| Total adverse events | 22 | 59 | 81 |
| Gastrointestinal | 13 | 32 | 45 |
| Abdominal pain | 2 | 2 | 4 |
| Decreased appetite | 0 | 4 | 4 |
| Diarrhea | 4 | 8 | 12 |
| Nausea | 3 | 9 | 12 |
| Vomiting | 2 | 9 | 11 |
| Reflux | 2 | 0 | 2 |
| Neurologic | 3 | 12 | 15 |
| Headache | 3 | 9 | 12 |
| Facial numbness | 0 | 1 | 1 |
| Altered mood | 0 | 2 | 2 |
| Cardiovascular | 3 | 7 | 10 |
| Chest pain | 1 | 1 | 2 |
| Flushing | 1 | 2 | 3 |
| Hypotension | 0 | 1 | 1 |
| Tachycardia with exercise | 0 | 1 | 1 |
| Dizziness | 1 | 1 | 2 |
| Pre-syncope | 0 | 1 | 1 |
| Respiratory | 2 | 5 | 7 |
| Shortness of breath | 1 | 1 | 2 |
| Decreased exercise tolerance | 0 | 2 | 2 |
| Decreased oxygen saturation | 1 | 2 | 3 |
| Musculoskeletal | 1 | 3 | 4 |
| Jaw pain | 0 | 1 | 1 |
| Leg pain | 0 | 1 | 1 |
| Back pain | 1 | 1 | 2 |
| Adverse reaction per patient (n (%)) | |||
| 0 | 1 (16.6) | 6 (27.2) | 7 (25) |
| 1 | 0 (0) | 3 (13.6) | 3 (10.7) |
| 2 | 0 (0) | 4 (18.2) | 4 (14.3) |
| 3–5 | 4 (66.8) | 6 (27.2) | 10 (35.7) |
| 6–9 | 1 (16.6) | 3 (13.6) | 4 (14.3) |
Number of adverse reactions by organ system that occurred during initial study period through 1 June 2017; includes initiation, transition, and maintenance.